Abstract:BackgroundCombination therapy with anti-CTLA-4 and anti-PD-1 mAbs has emerged as the most potent and durable cancer immunotherapy, yet it is associated with frequent and severe immune-related adverse events (irAEs).1 2 A largely unmet medical need is to reduce irAEs. The CD24–Siglec 10/G interaction is an emerging immune checkpoint that regulates inflammation caused by danger-associated molecular patterns (DAMPs).3–5 It is of great interest to investigate whether CD24Fc can ameliorate severe irAEs, the hallmark of which is a severe inflammatory state in multiple organs.MethodsWe used a human CTLA-4 knock-in (Ctla4h/h) mice model that fully recapitulates human irAE in response to anti-PD-1 and anti-CTLA-4 antibodies to test if CD24Fc have therapeutic effect for irAE. We treated Ctla4h/h mice with Ipilimumab and anti-PD-1 Ab in conjunction with hIgFc or CD24Fc on day 10, 13, 16 and 19 after birth. The body weight was monitored over time, hematologic and histopathologic alterations were evaluated at 6 weeks of age. To evaluate the therapeutic effect of CD24Fc on ICIs induced tissue destruction, we performed histological analysis of internal organs and glands. Major organs were collected about 1 month after first treatment and fixed in 10% formalin, sectioned and stained with hematoxylin and eosin (H&E), and scored double blindly. To test whether CD24Fc immune modulation may interfere with the anti-tumor efficacy of the checkpoint inhibitors, we inoculated MC38 and B16-F10 tumor cells on Ctla4h/h mice, then treated with combination of Ipilimumab and anti-PD-1 Ab together with hIgFc or CD24Fc and monitored tumor growth.ResultsWe found that anti-CTLA-4 and anti-PD-1 therapy could induce growth retardation, anemia and severe inflammation in all organs examined. All of these adverse events were ameliorated by CD24Fc treatment. Moreover, in both tumor models tested CD24Fc modestly enhanced immunotherapeutic effect of anti-PD-1 and anti-CTLA-4 antibodies. CD24Fc treatment showed no effect on CD4+, CD8+ T cell or tumor associated macrophage (TAM) density intratumor. However, we observed significantly decreased Treg among CD4+T cells after CD24Fc treatment. CD24Fc treatment also decreased the TIM-3+ PD-1+ CD4+ and CD8+ T cells. These data suggest CD24Fc has the potential to optimize tumor microenvironment and augment antitumor immunity.ConclusionsOur data demonstrate that CD24Fc treatment ameliorates irAEs in multiple organs induced by combination of anti-CTLA-4 and anti-PD-1 Abs while modestly enhancing its anti-tumor activity, potentially by reducing the intratumor regulatory T cells and reverse exhaustion of tumor-infiltrating T cells.ReferencesWolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345–1356.Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–1546.Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009;323:1722–1725.Liu Y, Chen GY, Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol 2009;30:557–561.Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol 2010;7:100–103.

CD24-Fc resolves inflammation and rescues CD8 T cells with polyfunctionality during HIV-1 infection under cART

Identification of CD98 As a Novel Biomarker for HIV-1 Permissiveness and Latent Infection

Killing HIV-infected Resting Central Memory CD4+ T Cells by Targeting Inhibitor of Apoptosis Proteins-Inhibited Autophagy

Plasmacytoid Dendritic Cells Impair HIV-specific CD8 T Cells to Maintain HIV-1 Reservoir Persistence During Chronic HIV Infection under Cart

813 CD24Fc Ameliorates Immune-Related Adverse Events While Preserving Anti-Tumor Therapeutic Effect

Plasmacytoid Dendritic Cells Impair Anti-HIV Immunity and HIV-1 Persistence During Antiretroviral Therapy Via IDO-Dependent Mechanisms

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

Distinct inflammation-related proteins associated with T cell immune recovery during chronic HIV-1 infection

Glycosylphosphatidylinositol- Anchored Anti-Hiv Scfv Efficiently Protects Cd4 T Cells from Hiv-1 Infection and Deletion in Hu-Pbl Mice

TLR3 Agonist and CD40-targeting Vaccination Induces Immune Responses and Reduces HIV-1 Reservoirs

Plasmacytoid Dendritic Cells Contribute to HIV Diseases and Viral Persistence Via IDO-dependent Mechanisms

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

Identification of CD8+ T cell subsets that normalize in early-treated people living with HIV receiving antiretroviral therapy

Diminished Peripheral CD29hi Cytotoxic CD4+ T Cells Are Associated With Deleterious Effects During SIV Infection

cART Restores Transient Responsiveness to IFN Type 1 in HIV-Infected Humanized Mice

Inhibition of caspase pathways limits CD4+ T cell loss and restores host anti-retroviral function in HIV-1 infected humanized mice with augmented lymphoid tissue

Alterations in circulating immunoregulatory proteins discriminate poor CD4 T lymphocyte trajectories in people with HIV on suppressive antiretroviral therapy

Targeting type I interferon–mediated activation restores immune function in chronic HIV infection

CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells

HIV-1-Specific CD11c+ CD8+ T Cells Display Low PD-1 Expression and Strong Anti-HIV-1 Activity